41st Annual J.P. Morgan Healthcare Conference

2022e revenue splits (directional) Consumables, biopharma development and mAb applications were the largest contributors CONSUMABLES/EQUIPMENT % of Total Revenue 25% R REPLIGEN 75% Equipment Consumables BIOPHARMA/CDMO/INTEGRATORS % of Total Revenue 17% 4% 29% 49% Biopharma Developers CDMOS Integrators Other 2022e total revenue reflects guidance midpoint as of our Q3 earnings call Nov. 1, 2022. BIOLOGIC TYPE 17% (COVID) 13% (C&GT) $138M TOTAL: $800M $105M 70% (mAbs) $557M 6

View entire presentation